1. Introduction {#sec1}
===============

With peak incidence occurring between 55 and 70 years of age, angle closure is a rare finding in children and young adults, which comprises less than 2.5% of the population with angle closure.[@bib1] Etiologies of angle closure in young patients may include plateau iris syndrome, iridociliary cysts, and retinopathy of prematurity (ROP) rather than primary relative pupillary block, which is more commonly seen in older individuals. Currently, there is no consensus among pediatric glaucoma specialists on the optimal surgical approach for juvenile angle closure, and the outcomes of surgical management remain uncertain.[@bib2] In this study, we examined the safety and efficacy of lens extraction/goniosynechialysis (LE-GSL) in the management of juvenile angle closure.

2. Materials and methods {#sec2}
========================

We performed a retrospective review of medical records in consecutive young patients with angle closure. Patient were identified using financial claims data, and were included for analysis if they were younger than 40 years of age at the time of diagnosis, had angle closure, had at least one month of post-operative follow up, and had undergone LE-GSL between January 1, 2015 and June 30, 2019. Patients whose records lacked sufficient detail in pre-operative angle anatomy and/or surgical techniques were excluded. Angle closure was defined as elevated untreated intraocular pressure (IOP) ≥ 24 mmHg and (1) less than 180° of visible trabecular meshwork, or (2) any peripheral anterior synechiae noted on gonioscopy, or (3) iridocorneal apposition prior to dilation of 180° or greater on anterior segment imaging. Glaucoma is defined as the presence of optic nerve damage based on structural/functional testing; those without glaucoma are considered glaucoma suspects.

The study was approved by the University of Miami Miller School of Medicine Institutional Review Board. It was fully compliant with the requirements of the United States Health Insurance Portability and Accountability Act and adherent to the tenets of the Declaration of Helsinki.

The following historical information was extracted from the review of medical records: sex, laterality, age of diagnosis, age at the time of surgery, number of pre-operative glaucoma medications, whether the patient had undergone retinal ablation for retinopathy of prematurity, pre-operative visual acuity (VA) and intraocular pressure (IOP), and maximum IOP (Tmax). The following intraoperative information was extracted: presence or absence of concurrent intraocular lens (IOL) implantation, vitrectomy, and endoscopic cyclophotocoagulation (ECP). Post-operatively, IOP at 3 and 6 months, final VA, final IOP, final number of glaucoma medications, and duration of follow up were recorded. While not always explicitly stated in the records, the decision to perform concurrent vitrectomy is usually based upon suspect vitreoretinal traction as prophylaxis against postsurgical retinal detachment, while ECP is offered if significant anterior rotation of the ciliary body is observed in order to rotate the ciliary body posteriorly. VA was converted to logarithmic minimum angle of resolution (log MAR) for statistical analysis, and paired, 2-tailed student t-tests with 95% confidence interval (*P* \< 0.05) were performed to note statistical significance between corresponding pre- and post-operative findings.

3. Results {#sec3}
==========

A total of seven patients (eleven eyes) were included in this series, including 8 eyes diagnosed with glaucoma and 3 eyes with suspected glaucoma. Patient baseline characteristics and preoperative, intraoperative and postoperative details are outlined in [Table 1](#tbl1){ref-type="table"}. More than two-thirds of the eyes had a history of retinal ablation for retinopathy of prematurity, and over half of the eyes received concurrent IOL implantation and vitrectomy. None of the patients had anterior segment neovascularization.Table 1Patient baseline characteristics and concurrent intraocular procedures.Table 1DemographicsPreoperativeIntraoperativePostoperativePatient NumberSexAge onsetAge surgeryR/LROP laserVATmaxIOPDropsOral CAIIOLVitGSLECP3 mo IOP6 mo IOPFinal IOPFinal VAFinal meds1F1024RYes20/805083YesYesNoYesNo11111120/7002F3637RYesHM62170NoNoYesYesNoNANA8CF02F3637LYes20/20055104YesNoYesYesNo10121220/7003F1011RYes20/15030242NoNoYesYesYes10NA1720/20003F1010LYesCF29212NoNoYesYesYes20102120/35004F1717RYes20/80031314YesYesNoYesNo15NA1520/80005F2526RYes20/6034152NoYesNoYesYes1411520/3005F2527LYes20/5044212NoYesNoYesYes1111520/3006M1616LNo20/4028162NoYesYesYesNo16111320/2506M1617RNo20/2529161NoYesYesYesNo12121120/2007F811LNo20/2030211NoYesNoYesNo16121220/250[^1][^2][^3]

A comparison of visual acuity, IOP, and glaucoma medication burden before and after LE/GSL is outlined in [Table 2](#tbl2){ref-type="table"}. Patients were followed-up for a mean (SD) length of 13.7 months (11.5) with no intra- or post-operative complications in any eyes. Following the surgery, there was a statistically significant improvement in VA and a statistically significant decrease in IOP (35.2% reduction; *P* = 0.009) after a mean follow up of 13.7±11.5 months. The number of glaucoma medications (topical and systemic) significantly reduced from a mean (SD) of 2.4 (1.6) pre-operatively to no medications at final follow-up (difference −2.4; 95% CI, −2.7 to −2.0; *P* \< 0.001). Excluding the four eyes that had undergone ECP, there is a 31.1% reduction in IOP (preoperative IOP 17.0 mmHg preoperatively and 11.7 mmHg postoperatively), although this comparison failed to reach statistical significance (*P = 0.10*) due to the small sample size. There is a significant reduction in the number of medications (from mean of 2.14 preoperatively to zero postoperative).Table 2Comparison of visual acuity, intraocular pressure and glaucoma medication burden before and after lens extraction-goniosynechialysis.Table 2Mean (SD)CharacteristicPre-operativePost-operativeMean difference (95% CI)*P-value*VA (logMAR)0.88 (0.77)[a](#tbl2fna){ref-type="table-fn"}0.68 (0.68)[b](#tbl2fnb){ref-type="table-fn"}−0.20 (−0.25 to −0.15)0.029IOP (mmHg)[c](#tbl2fnc){ref-type="table-fn"}18.2 (6.4)3 months (N = 10)13.5 (3.3)−5.9 (−7.4 to −4.5)0.0436 months (N = 8)11.3 (0.7)−4.8 (−6.0 to −3.5)0.037Final follow up (N = 11)11.8 (4.8)−6.4 (−7.7 to −5.0)0.009Number of glaucoma medications (N)2.4 (1.6)0 (0)−2.4 (−2.7 to −2.0)\<0.001Topical medications2.1 (1.2)0 (0)−2.1Systemic CAI0.3 (0.5)0 (0)−0.3Mean follow up duration (months)13.7 (11.5)[^4][^5][^6]

4. Discussion {#sec4}
=============

Angle closure in young patients present significant management challenges. The shallow anterior chamber in a phakic eye increases the risk of choroidal effusion and corneal decompensation, while the patient\'s young age increases the cumulative risk of bleb-forming procedures.[@bib3] The role of lens extraction (with or without concurrent goniosynechialysis) in adult-onset angle closure is well validated.[@bib4] However, to the authors\' knowledge, this is the first study to evaluate the safety and efficacy of LE-GSL in the treatment of angle closure in patients younger than 40 years of age. In our cohort, all patients were able to discontinue glaucoma medications, and the large majority of patients achieved significant improvements in IOP and VA without requiring a bleb-forming glaucoma procedure.

Since angle closure is an uncommon finding in young patients, there are few reports on the efficacy of GSL in this patient population (age \< 40 years). A retrospective study by Kameda et al. indicates that for 109 patients treated with phacoemulsification and GSL "younger age is a risk factor for surgical failure."[@bib5] The authors implicated a more robust post-operative wound healing response and inflammatory reaction as potential attributing factors to the increased risk of failure, defined as (1) persistent IOP≥21 mmHg, (2) IOP values of ≥18 mmHg, with or without topical ocular medication, at two consecutive follow-up visits, or (3) additional operations needed. However, the lowest age within the range of this study cohort was 47 years (mean age 70±9.4). Therefore, additional studies will be required to support this claim within the younger patient population.

Furthermore, the pathophysiology of AC in juvenile patients may vary quite dramatically from that of older individuals, which typically results from relative pupillary block (RPB). While RPB still occurs in the juvenile population, the angle closure is often attributed to congenital structural abnormalities rather than age-related phacomorphic lens enlargement. For example, nanophthalmos, which is common in congenital ocular syndromes, presents with short axial length, hyperopia, narrowed angles, and an enlarged lens-to-ocular volume ratio leading to pupillary block.[@bib1] Similarly, anterior segment under-development following infantile retinal ablation for retinopathy of prematurity (8 out of 11 patients in our case series) can cause anterior displacement of the lens-iris diaphragm and result in AC that is refractory to LPI. This proposed pathophysiology suggest that the removal of lens followed by goniosynechialysis has reasonable prospect for restoring the trabecular outflow and controlling 10.13039/501100000640IOP, and our findings support this notion.

Limitations of this study include retrospective design, modest sample size, and variable lengths of follow-up. Furthermore, the true efficacy of LE-GSL could not be assessed since the majority of our cohort also had concurrent PPV and/or ECP. However, given the low incidence of juvenile angle closure, designing and implementing a prospective study would be challenging. This study also has weaknesses inherent to all retrospective clinical studies.

In conclusion, our case series demonstrated that LE-GSL is a safe and efficacious surgical option that can significantly lower IOP, improve visual outcomes, and alleviate medication burden in young angle closure patients.
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[^1]: Key -- CAI (carbonic anhydrase inhibitor), CF (count finger), Drops (number of topical pressure-lowering agents), ECP (endocyclophotocoagulation), F (female), GSL (goniosynechialysis), HM (hand-motion).

[^2]: IOL (intraocular lens implantation), IOP (intraocular pressure), M (male), mo (months), meds (total number of topical and oral pressure-lowering agents), NA (not available).

[^3]: R/L (right versus left eye; R right, L left), ROP (retinopathy of prematurity), Tmax (maximum intraocular pressure during follow up period, in mmHg), VA (visual acuity), Vit (vitrectomy).

[^4]: Snellen equivalence of 20/150.

[^5]: Snellen equivalence of 20/100.

[^6]: Mean maximum pre-operative IOP during study period = 38.4±12.2 mmHg; Abbreviations: SD (standard deviation), CI (confidence interval), logMAR (logarithmic minimum angle of resolution), CAI (carbonic anhydrase inhibitor).
